Gastroenteropancreatic Neuroendocrine Tumor Market on Track for Major Expansion by 2034, According to DelveInsight

DelveInsight's "Gastroenteropancreatic Neuroendocrine Tumor Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Gastroenteropancreatic Neuroendocrine Tumor, historical and forecasted epidemiology as well as the Gastroenteropancreatic Neuroendocrine Tumor market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Gastroenteropancreatic Neuroendocrine Tumor market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; GEP-NETs Market Forecast
https://www.delveinsight.com/sample-request/gastroenteropancreatic-neuroendocrine-tumors-gep-nets-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Gastroenteropancreatic Neuroendocrine Tumor Market Report:
• The Gastroenteropancreatic Neuroendocrine Tumor market size is anticipated to grow with a significant CAGR during the study period (2020-2034).
• In November 2025, ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, announced that the U.S. Food and Drug Administration (FDA) has completed its filing review and accepted the company's New Drug Application (NDA) for n.c.a. 177Lu-edotreotide (also known as ITM-11 or 177Lu-edotreotide). This proprietary, synthetic, targeted radiotherapeutic investigational agent is being developed by ITM for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The FDA has established a Prescription Drug User Fee Act (PDUFA) target action date of August 28, 2026.
• GEP-NETs are the second most prevalent type of digestive cancer.
• Findings indicate that the most common primary sites for NETs in the digestive tract are the small intestine (30.8%), rectm (26.3%), colon (17.6%), pancreas (12.1%), and appendix (5.7%).
• The findings show that at diagnosis, 53% of NET patients have localized disease, 20% present with locoregional disease, and 27% have distant metastases.
• Key Gastroenteropancreatic Neuroendocrine Tumor Companies: ITM Isotope Technologies Munich, Camurus, RayzeBio, Merck Sharp & Dohme, Ipsen, Advanced Accelerator, Jiangsu HengRui Medicine, Camurus AB, Novartis, Tarveda Therapeutics, Progenics Pharmaceuticals, Pharmacyclics, and others
• Key Gastroenteropancreatic Neuroendocrine Tumor Therapies: SOMATULINE DEPOT, ITM-11, CAM2029, RYZ101, Lanreotide, arginine, lysine, Temozolomide (TMZ), Lutetium (177Lu) Oxodotreotide Injection, CAM2029, Everolimus, PEN-221, Lutathera, Ibrutinib, and others
• The Gastroenteropancreatic Neuroendocrine Tumor epidemiology based on gender analyzed that the incidence of functional GEP-NET is more than that of nonfunctional GEP-NET in the United States
• The Gastroenteropancreatic Neuroendocrine Tumor market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Gastroenteropancreatic Neuroendocrine Tumor pipeline products will significantly revolutionize the Gastroenteropancreatic Neuroendocrine Tumor market dynamics.

Gastroenteropancreatic Neuroendocrine Tumor Overview
Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) are a diverse group of tumors that arise from neuroendocrine cells in the gastrointestinal (GI) tract and pancreas. These cells have both endocrine and neural characteristics and are responsible for producing hormones that regulate various physiological functions.

Get a Free sample for the Gastroenteropancreatic Neuroendocrine Tumor Market Report:
https://www.delveinsight.com/report-store/gastroenteropancreatic-neuroendocrine-tumors-gep-nets-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Gastroenteropancreatic Neuroendocrine Tumor Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Gastroenteropancreatic Neuroendocrine Tumor Epidemiology Segmentation:
The Gastroenteropancreatic Neuroendocrine Tumor market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Incident Cases of GEP-NET in the 7MM
• Grade-Specific Cases of GEP-NET in the 7MM
• Tumor site-specific Cases of GEP-NET in the 7MM
• Stage-specific Cases of GEP-NET in the 7MM
• Symptom-specific Cases of GEP-NET in the 7MM

Download the report to understand which factors are driving GEP-NETs epidemiology trends @ Gastroenteropancreatic Neuroendocrine Tumor Epidemiology Forecast
https://www.delveinsight.com/sample-request/gastroenteropancreatic-neuroendocrine-tumors-gep-nets-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Gastroenteropancreatic Neuroendocrine Tumor Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Gastroenteropancreatic Neuroendocrine Tumor market or expected to get launched during the study period. The analysis covers Gastroenteropancreatic Neuroendocrine Tumor market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Gastroenteropancreatic Neuroendocrine Tumor Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Gastroenteropancreatic Neuroendocrine Tumor Therapies and Key Companies
• SOMATULINE DEPOT: Ipsen Biopharmaceuticals
• ITM-11: ITM Isotope Technologies Munich
• CAM2029: Camurus
• RYZ101: RayzeBio
• Lanreotide: Merck Sharp & Dohme
• arginine/lysine: Advanced Accelerator
• Temozolomide (TMZ): Ipsen
• Lutetium (177Lu) Oxodotreotide Injection: Jiangsu HengRui Medicine
• RYZ101: RayzeBio, Inc.
• CAM2029: Camurus AB
• Everolimus: Novartis
• PEN-221: Tarveda Therapeutics
• Lutathera: Progenics Pharmaceuticals
• Ibrutinib: Pharmacyclics

Discover more about therapies set to grab major GEP-NETs market share @ Gastroenteropancreatic Neuroendocrine Tumor Treatment Market
https://www.delveinsight.com/sample-request/gastroenteropancreatic-neuroendocrine-tumors-gep-nets-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Gastroenteropancreatic Neuroendocrine Tumor Market Strengths
• GEP-NETs are often diagnosed at an early stage due to the hormonal symptoms they produce, allowing for timely intervention and better outcomes.
• Treatment of GEP-NETs involves a multidisciplinary team of specialists, including oncologists, surgeons, and endocrinologists, which enhances the overall management of the disease.

Gastroenteropancreatic Neuroendocrine Tumor Market Opportunities
• Continued research and development in targeted therapies, such as somatostatin analogs and molecular inhibitors, provide opportunities for more effective and personalized treatment approaches.
• Participation in clinical trials can lead to the discovery of new treatment modalities and contribute to the improvement of patient outcomes.

Scope of the Gastroenteropancreatic Neuroendocrine Tumor Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Gastroenteropancreatic Neuroendocrine Tumor Companies: ITM Isotope Technologies Munich, Camurus, RayzeBio, Merck Sharp & Dohme, Ipsen, Advanced Accelerator, Jiangsu HengRui Medicine, Camurus AB, Novartis, Tarveda Therapeutics, Progenics Pharmaceuticals, Pharmacyclics, and others
• Key Gastroenteropancreatic Neuroendocrine Tumor Therapies: SOMATULINE DEPOT, ITM-11, CAM2029, RYZ101, Lanreotide, arginine, lysine, Temozolomide (TMZ), Lutetium (177Lu) Oxodotreotide Injection, CAM2029, Everolimus, PEN-221, Lutathera, Ibrutinib, and others
• Gastroenteropancreatic Neuroendocrine Tumor Therapeutic Assessment: Gastroenteropancreatic Neuroendocrine Tumor current marketed and Gastroenteropancreatic Neuroendocrine Tumor emerging therapies
• Gastroenteropancreatic Neuroendocrine Tumor Market Dynamics: Gastroenteropancreatic Neuroendocrine Tumor market drivers and Gastroenteropancreatic Neuroendocrine Tumor market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Gastroenteropancreatic Neuroendocrine Tumor Unmet Needs, KOL's views, Analyst's views, Gastroenteropancreatic Neuroendocrine Tumor Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.